What We're Reading: Page 273
Industry reads hand-picked by our editors
Feb 21, 2018
Feb 20, 2018
-
The Boston Globe
2 pharma giants, Calif. hospital to use Boston firm’s ‘organ-on-a-chip’ to develop drugs
-
NPR
Did pox virus research put potential profits ahead of public safety?
-
Chemical & Engineering News
Japanese firms push into cell therapy
-
Retail Dive
Chinese pharma company grabs major stake in GNC
-
The New York Times
Doctors said immunotherapy would not cure her cancer. They were wrong.
Feb 16, 2018
Feb 15, 2018
-
Bloomberg Gadfly
Buffett just messed things up for Teva short-sellers
-
Boston Business Journal
Cambridge biotech startup seeking to repurpose Vioxx raises $5M
-
Reuters
French pharma group Ipsen sees more asset purchases, U.S. growth
-
Time
Inside one couple’s experimental treatment to battle Alzheimer’s disease
Feb 14, 2018
-
Bloomberg
What stands between Bezos, Buffett, and Dimon and a health-care fix
-
Associated Press
Can gene therapy be harnessed to fight the AIDS virus?
-
Quartz
This year’s dismal flu season is helping pharmacy stocks
-
GeekWire
Pittsburgh research giants unveil landmark $200M immunotherapy center to combat cancer and aging
-
Merck & Co.
Merck delivers latest Alzheimer's disappointment
Feb 13, 2018
-
Undark
If a pharma company publishes a magazine, is it journalism?
-
The Washington Post
Former pharma exec, Christie backer seeks to oust Menendez
-
Reuters
Germany's CureVac wins new vaccine funding from Gates Foundation
-
The New York Times
He took a drug to prevent AIDS. Then he couldn’t get disability insurance.
Feb 12, 2018
-
The New York Times
F.D.A. chief goes against the administration stereotype
-
FT
Amgen 'looking hard' at striking deals using $27B cash pile
-
The Denver Post
CEO of Colorado biotech-turned-blockchain company explains why he sold stock after price quadrupled
-
The Boston Globe
Japanese executives ponder investing in Mass.
Previous
